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DVT = deep vein thrombosis; ICU = intensive care unit; LMWH = low-molecular-weight heparin; VTE = venous thromboembolism.
Available online http://ccforum.com/content/5/6/277
Deep vein thrombosis (DVT) remains an underestimated
problem in ICU patients, despite the findings of many
randomized controlled trials performed in the field of DVT
prophylaxis after surgery during the past few decades [1,2].
Several consensus statements have been reported [3–5] that
summarize the conclusions of those studies. The Canadian
survey reported in the present issue of Critical Care
(page 336) provides a useful snapshot of daily clinical
practice in Canada with regard to DVT prophylaxis [6]. It
strongly suggests that studies dedicated to DVT prophylaxis
in ICU patients should be performed in order to develop
useful recommendations. Furthermore, a great effort would
have to be made to educate physicians regarding both DVT
screening and pharmacological aspects.
A difficult diagnosis
Clinicians should be aware that DVT in ICU patients has
unusual characteristics that make its clinical diagnosis
difficult. Physical examination is rarely helpful because DVT is
generally asymptomatic. This was demonstrated in the study
of Geerts et al. [7], in which the clinical signs of DVT (e.g.
oedema, pain and flushing) occurred in less than 1.5% of
patients. As a result, physicians are often lulled into an
inappropriate sense of security. Moreover, the diagnosis is
not always easy to confirm. The insensitivity of Doppler
ultrasound and the major difficulty in performing venography
in ICU patients generally lead to blind anticoagulant
prophylaxis. Even when a pulmonary embolism leads to
death, diagnosis is often difficult to confirm in a patient who
has already been treated and ventilated for a pulmonary
condition because autopsies are rarely conducted in trauma
victims. As stated at the most recent American College of
Chest Physicians Consensus Conference [5], however,
trauma patients represent a group that is at very high risk for
DVT. The discussion should therefore no longer focus on the
incidence of thrombosis, but rather on the different methods
of prevention that could be used.
Traditional and advanced compression
techniques
Graded elastic stockings do not provide adequate
prophylaxis in high-risk patients [5,8,9]. Most of the Canadian
respondents in the survey appear to be aware of this, which
would explain why up to 34% of ICU directors do not
consider mechanical prophylaxis at all. It has been strongly
suggested, however, that elastic stockings should be
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Abstract
The survey of how Canadian intensive care units (ICUs) prevent and diagnose venous
thromboembolism (VTE) presented in this issue of Critical Care illustrates considerable variability. Lack
of optimal patient care reflects how VTE is rated in ICUs. The discussion should no longer focus on the
incidence of thrombosis, but rather on its prevention. Unfractionated heparin remains the most
commonly used agent to prevent VTE, despite the recognized efficacy and safety of low-molecular-
weight heparins (LMWHs) in the ICU setting. In addition, too few ICU directors consider the use of
mechanical prophylactic measures, such as graded elastic stockings and venous foot pump. The
present situation calls for large randomized controlled trials in either medical or surgical ICU patients,
and for new education programmes in order to modify the care of ICU patients with regard to VTE.
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combined with LMWH [3–5]. Combining noninvasive with
pharmacological prophylaxis has been shown to be beneficial
[3], and should therefore be encouraged. It is also cost-
effective and easy to use.
In order to improve the benefit from such combinations of
mechanical and pharmacological measures, new mechanical
devices for DVT prophylaxis are being developed. Classic
intermittent pneumatic compression devices applied directly
to the entire leg are often difficult to use because of
fractures, immobilization with plaster casts, or external fixation
instruments. With a venous foot pump these difficulties are
eliminated. The foot pump is designed to overcome the
venous stasis that is associated with surgery. It flattens the
metatarsal arch, emptying the venous plexus (30 ml blood)
and thus reproducing the effect of normal weight-bearing.
The efficacy of the foot pump has already been demonstrated
in level II and III studies.
A recent large, prospective, randomized study conducted in
274 patients with total hip replacement [10] compared the
safety and effectiveness of the foot pump with those of
LMWH prophylaxis. That study showed no significant
difference between the two methods; DVT was detected in
24 (18%) patients randomized to foot pump prophylaxis as
compared with 18 patients (13%) randomized to receive the
LMWH enoxaparin. There was no difference in the
transfusion requirements or intraoperative blood losses
between the two groups. This new method could be helpful
in trauma, neurological, or neurosurgical patients when
anticoagulants are contraindicated.
In summary, mechanical prophylaxis should systematically be
used alone or in combination with pharmacological
prophylaxis in ICU patients.
Unfractionated versus low-molecular-weight
heparin
Although unfractionated heparin (5000 IU administered
subcutaneously two or three times per day) is used
extensively in the Canadian centres, there is considerable
evidence [2–5,11,12] that these small doses of heparin are
relatively ineffective in comparison with doses used in
orthopaedic surgery. In the literature, selection of
unfractionated heparin was supported by DVT detection
methods, such as echography and Duplex scanning. These
methods are unacceptable because of their low sensitivity in
asymptomatic patients, especially in the ICU. Administration of
LMWH has been shown to result in significantly better results.
In 1996, Geerts et al. [13] showed that 30 mg enoxaparin
given twice daily exhibited superior antithrombotic efficacy as
compared with subcutaneous heparin 5000 IU twice daily.
The overall venographic DVT rate was reduced from 44 to
31%, and the proximal DVT rate from 15 to 6% in patients
receiving heparin and enoxaparin, respectively. Since then,
only one relevant study has been reported, which compared
LMWH with placebo in ICU patients [14]. In that study,
nadroparin was able to decrease the DVT rate significantly,
but no direct comparison between LMWH and
unfractionated heparin was undertaken.
Although there is still insufficient data in the ICU setting, the
large amount of data gathered by surgical trials should allow
extrapolation. LMWH appears to be effective and safe
postoperatively, and hence should probably be
recommended in ICU patients except when renal function is
impaired and in very old patients [15,16]. The optimal
duration of treatment has not been defined, but it appears
reasonable to suggest that prophylaxis with LMWH should
be continued for as long as risk factors are present, such as
inflammation, sepsis and immobilization.
New compounds such as recombinant hirudin [17] and
pentasaccharide [18] should be evaluated in these very high
risk patients because those agents have exhibited high
efficacy in preventing DVT after total hip replacement
surgery. They may be particularly useful in those settings in
which thrombotic risk rapidly exceeds haemorrhagic risk. Oral
anticoagulants cannot be recommended in trauma patients
because some have to undergo multiple surgical procedures.
In addition, interactions between vitamin K antagonists and
other drugs used in this setting may be hazardous.
Conclusion
Thrombotic complications (DVT, pulmonary emboli) are a
major concern in ICU patients and still occur in a significant
number of patients. Antithrombotic agents, and LMWH in
particular, should be considered in a systematic manner,
except for those cases in which they are contraindicated. The
optimal dosage for prophylaxis with LMWH is not well
defined. Pharmacological prophylaxis should always be
combined with mechanical prophylaxis. Large randomized
controlled trials are needed to confirm these
recommendations. Finally, educational programmes should
be implemented that include epidemiological and therapeutic
aspects of VTE prevention.
Competing interests
None declared.
References
1. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A:
Prevention of postoperative venous thrombosis: a random-
ized trial comparing unfractionated heparin with low molecu-
lar weight heparin in patients undergoing total hip
replacement. Thromb Haemost 1988, 60:407-410.
2. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP:
Low molecular weight heparin in the prevention of peri-opera-
tive thrombosis. BMJ 1992, 305:913-920.
3. Anonymous: Prevention of venous thromboembolism. Interna-
tional Consensus Statement (guidelines according to scien-
tific evidence). Intern Angiol 1997, 16:3-38.
4. Clagett GP, Anderson FA, Geerts W, Heit J, Knudson M, Lieber-
man JR, Merli GJ, Wheeler HB: Prevention of venous throm-
boembolism. Chest 1998, 114(suppl):531S-560S.r
e
s
e
a
r
c
h
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
m
e
e
t
i
n
g
 
a
b
s
t
r
a
c
t
s
5. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Ander-
son FA Jr, Wheeler HB: Prevention of venous thrombo-
embolism. Chest 2001, 119(suppl):132S-175S.
6. Cook D, McMullin J, Hodder R, Heule M, Pinilla J, Dodek P,
Stewart T, for the Canadian ICU Directors Group: Prevention
and diagnosis of venous thromboembolism in critically ill
patients: a Canadian survey. Crit Care 2001, 5:336-342.
7. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP: A prospective
study of venous thromboembolism after major trauma. N Engl
J Med 1994, 331:1601-1606.
8. Patel A, Couband D, Feron JM, Signoret F: Prévention des
thromboses veineuses profondes lors de la chirurgie arthro-
plastique de hanche par l’association héparinothérapie-bas
antithrombose  [Prevention of deep venous thrombosis in
arthroplastic surgery of the hip by the combination of
heparinotherapy and the antithrombosis stocking]. Presse
Med 1988, 17:1201-1203.
9. Wells PS, Lensing AWA, Hirsh J: Graduated compression
stockings in the prevention of postoperative venous throm-
boembolism. Arch Intern Med 1994, 154:67-72.
10. Warwick D, Harrisson J, Glew D, Mitchelmore A, Peters TJ,
Donovan J: Comparison of the use of a foot pump with the use
of low molecular weight heparin for the prevention of deep
vein thrombosis after total hip replacement. J Bone J Surg
1998, 80A:1158-1166.
11. Knudson MM, Collins JA, Goodman SB, McCrory DW: Throm-
boembolism following multiple trauma. J Trauma 1992, 32:2-
11.
12. Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J: Pre-
vention of venous thromboembolism in trauma patients. J
Trauma 1994, 37:480-487.
13. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamil-
ton PA: A comparison of low-dose heparin with low molecular
weight heparin as prophylaxis against venous thromboem-
bolism after major trauma. N Eng J Med 1996, 335:701-707.
14. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B,
Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L: Nadroparin
in the prevention of deep vein thrombosis in acute decom-
pensated COPD. The Association of Non-University Affiliated
Intensive Care Specialist Physicians of France. Am Rev Respir
Crit Care Med 2000, 161:1109-1114.
15. Knudson MM, Morabito D, Paiement GD, Shackleford S: Use of
low molecular weight heparin in preventing thromboem-
bolism in trauma patients. J Trauma 1996, 41:446-459.
16. Samama CM, Orliaguet G, Sztark F, Perrotin D: Prévention de la
maladie thromboembolique en réanimation: méthodes
mécaniques et moyens médicamenteux; indications et
contre-indications [Venous thromboembolism in the ICU:
mechanical and pharacological prophylaxis; indications and
contraindications]. Reanimation 2001, 10:462-472.
17. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N,
Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P: A com-
parison of recombinant hirudin with a low-molecular-weight
heparin to prevent thromboembolic complications after total
hip replacement. N Engl J Med 1997, 337:1329-1335.
18. Turpie AGG, Gallus AS, Hoek JA, for the Pentasaccharide investi-
gators: A synthetic pentasaccaride for the prevention of deep-
vein thrombosis after total hip replacement. N Engl J Med
2001, 344:619-625.
Available online http://ccforum.com/content/5/6/277